Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis
2 other identifiers
interventional
2,038
15 countries
140
Brief Summary
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2005
Shorter than P25 for phase_3
140 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2005
CompletedFirst Posted
Study publicly available on registry
November 10, 2005
CompletedStudy Start
First participant enrolled
December 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedResults Posted
Study results publicly available
March 23, 2009
CompletedFebruary 3, 2012
February 1, 2012
1.1 years
November 8, 2005
February 20, 2009
February 1, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.
8 Weeks
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
8 weeks
Secondary Outcomes (4)
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
8 Weeks
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
8 Weeks
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.
4 Weeks
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.
4 Weeks
Study Arms (3)
Dexlansoprazole MR 60 mg QD
EXPERIMENTALDexlansoprazole MR 90 mg QD
EXPERIMENTALLansoprazole 30 mg QD
ACTIVE COMPARATORInterventions
Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Eligibility Criteria
You may qualify if:
- Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D)
You may not qualify if:
- Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.
- Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics
- Use of antacids \[except for study supplied Gelusil®\]
- Need for continuous anticoagulant therapy (blood thinners)
- Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus
- History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)
- Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.
- History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.
- Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Takedalead
Study Sites (140)
Unknown Facility
Alabaster, Alabama, United States
Unknown Facility
Birmingham, Alabama, United States
Unknown Facility
Huntsville, Alabama, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Scottsdale, Arizona, United States
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Anaheim, California, United States
Unknown Facility
Chula Vista, California, United States
Unknown Facility
Fullerton, California, United States
Unknown Facility
Garden Grove, California, United States
Unknown Facility
Irvine, California, United States
Unknown Facility
Lancaster, California, United States
Unknown Facility
Long Beach, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Mission Hills, California, United States
Unknown Facility
Palm Springs, California, United States
Unknown Facility
Pasadena, California, United States
Unknown Facility
Redwood City, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
San Luis Obispo, California, United States
Unknown Facility
Boulder, Colorado, United States
Unknown Facility
Colorado Springs, Colorado, United States
Unknown Facility
Lone Tree, Colorado, United States
Unknown Facility
Wheat Ridge, Colorado, United States
Unknown Facility
Waterbury, Connecticut, United States
Unknown Facility
Boynton Beach, Florida, United States
Unknown Facility
Jacksonsville, Florida, United States
Unknown Facility
Jupiter, Florida, United States
Unknown Facility
Kissimmee, Florida, United States
Unknown Facility
Lakeland, Florida, United States
Unknown Facility
New Port Richey, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Honolulu, Hawaii, United States
Unknown Facility
Arlington Heights, Illinois, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Hines, Illinois, United States
Unknown Facility
Oak Park, Illinois, United States
Unknown Facility
Rockford, Illinois, United States
Unknown Facility
Clive, Iowa, United States
Unknown Facility
Dubuque, Iowa, United States
Unknown Facility
Newton, Kansas, United States
Unknown Facility
Shawnee Mission, Kansas, United States
Unknown Facility
Topeka, Kansas, United States
Unknown Facility
Metairie, Louisiana, United States
Unknown Facility
Shreveport, Louisiana, United States
Unknown Facility
Hollywood, Maryland, United States
Unknown Facility
Lutherville, Maryland, United States
Unknown Facility
Troy, Michigan, United States
Unknown Facility
Chaska, Minnesota, United States
Unknown Facility
Jackson, Mississippi, United States
Unknown Facility
Mexico, Missouri, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Washington, Missouri, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Pahrump, Nevada, United States
Unknown Facility
Binghamton, New York, United States
Unknown Facility
Brooklyn, New York, United States
Unknown Facility
Great Neck, New York, United States
Unknown Facility
Rochester, New York, United States
Unknown Facility
Charlotte, North Carolina, United States
Unknown Facility
Elkin, North Carolina, United States
Unknown Facility
Greensboro, North Carolina, United States
Unknown Facility
Hickory, North Carolina, United States
Unknown Facility
Salisbury, North Carolina, United States
Unknown Facility
Statesville, North Carolina, United States
Unknown Facility
Winston-Salem, North Carolina, United States
Unknown Facility
Beachwood, Ohio, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Mayfield Heights, Ohio, United States
Unknown Facility
Warren, Ohio, United States
Unknown Facility
Oklahoma City, Oklahoma, United States
Unknown Facility
Portland, Oregon, United States
Unknown Facility
Beaver Falls, Pennsylvania, United States
Unknown Facility
Duncansville, Pennsylvania, United States
Unknown Facility
Lansdale, Pennsylvania, United States
Unknown Facility
Bristol, Tennessee, United States
Unknown Facility
Chattanooga, Tennessee, United States
Unknown Facility
Hermitage, Tennessee, United States
Unknown Facility
Nashville, Tennessee, United States
Unknown Facility
Austin, Texas, United States
Unknown Facility
Beaumont, Texas, United States
Unknown Facility
Byran, Texas, United States
Unknown Facility
Corsicana, Texas, United States
Unknown Facility
El Paso, Texas, United States
Unknown Facility
Fort Worth, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Bountiful, Utah, United States
Unknown Facility
Ogden, Utah, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
West Jordan, Utah, United States
Unknown Facility
Chesapeake, Virginia, United States
Unknown Facility
Danville, Virginia, United States
Unknown Facility
Spokane, Washington, United States
Unknown Facility
Milwaukee, Wisconsin, United States
Unknown Facility
Monroe, Wisconsin, United States
Unknown Facility
Box Hill, Australia
Unknown Facility
South Brisbane, Australia
Unknown Facility
Sofia, Bulgaria
Unknown Facility
Edmonton, Alberta, Canada
Unknown Facility
Winnipeg, Manitoba, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, Canada
Unknown Facility
Québec, Quebec, Canada
Unknown Facility
Regina, Saskatchewan, Canada
Unknown Facility
Saskatoon, Saskatchewan, Canada
Unknown Facility
Prague, Czechia
Unknown Facility
Hamburg, Hamburg, Germany
Unknown Facility
Dietzenback, Hesse, Germany
Unknown Facility
Schweim, North Rhine-Westphalia, Germany
Unknown Facility
Borna, Saxony, Germany
Unknown Facility
Gyula, Hungary
Unknown Facility
Gujarat, Ahmedabad, India
Unknown Facility
Tamilnadu, Chennai, India
Unknown Facility
Rajasthan, Jaipur, India
Unknown Facility
Ludhiana, Punjab, India
Unknown Facility
Madurai, Tamina, India
Unknown Facility
Chennai, India
Unknown Facility
Coimbatore, India
Unknown Facility
Hyderabad, India
Unknown Facility
New Delhi, India
Unknown Facility
Visakhapatnam, India
Unknown Facility
Riga, Latvia
Unknown Facility
Kaunas, Lithuania
Unknown Facility
Hamilton, New Zealand
Unknown Facility
Lima, Peru
Unknown Facility
Krakow, Poland
Unknown Facility
Lubin, Poland
Unknown Facility
Sopot, Poland
Unknown Facility
Warzawa, Poland
Unknown Facility
Bratislava, Slovakia
Unknown Facility
Nitra, Slovakia
Unknown Facility
Sučany, Slovakia
Unknown Facility
Tmava, Slovakia
Unknown Facility
Gauteng, Johannesburg, South Africa
Unknown Facility
Cape Town, WC, South Africa
Unknown Facility
Panorama, WC, South Africa
Unknown Facility
Pinelands, WC, South Africa
Unknown Facility
Plumstead, WC, South Africa
Unknown Facility
Somerset West, WC, South Africa
Unknown Facility
Pretoria, South Africa
Related Publications (6)
Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. Aliment Pharmacol Ther. 2009 Apr 1;29(7):731-41. doi: 10.1111/j.1365-2036.2009.03933.x.
PMID: 19183157RESULTPeura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1010-21. doi: 10.1111/j.1365-2036.2009.04137.x. Epub 2009 Sep 4.
PMID: 19735233RESULTWyrwich KW, Mody R, Larsen LM, Lee M, Harnam N, Revicki DA. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants. Qual Life Res. 2010 May;19(4):551-64. doi: 10.1007/s11136-010-9620-x. Epub 2010 Feb 27.
PMID: 20195905RESULTFriedlander EA, Pallentino J, Miller SK, VanBeuge SS. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract. 2010 Dec;22(12):674-83. doi: 10.1111/j.1745-7599.2010.00578.x. Epub 2010 Nov 24.
PMID: 21129076RESULTPeura DA, Pilmer B, Hunt B, Mody R, Perez MC. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30.
PMID: 24118079DERIVEDPeura DA, Pilmer B, Hunt B, Mody R, Perez MC. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther. 2013 Apr;37(8):810-8. doi: 10.1111/apt.12270. Epub 2013 Mar 4.
PMID: 23451835DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Sr. VP Clinical Sciences
- Organization
- Takeda Global Research and Development Center, Inc.
Study Officials
- STUDY CHAIR
Medical Director
Takeda
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2005
First Posted
November 10, 2005
Study Start
December 1, 2005
Primary Completion
January 1, 2007
Study Completion
January 1, 2007
Last Updated
February 3, 2012
Results First Posted
March 23, 2009
Record last verified: 2012-02